Jefferies & Co

Analysts at Jefferies & Co reiterate their "buy" rating on Walt Disney Co (NYSE: DIS), while raising their estimates for the company. The target price for DIS is set to $41. Jefferies & Co says, “DIS reported EPS of $0.67, 8c ahead of our $0.59 est and 9c ahead of Consensus. Strong...

Analysts at Jefferies & Co reiterate their "hold" rating on Lions Gate (NYSE: LGF). The target price for LGF is set to $7. According to Jefferies & Co, “LGF reported a surprising F1Q11 EBITDA loss of $35.8MM vs. $48.5MM profit last year. Theatrical marketing costs associated with 3 wide...

Jefferies & Company is out with a research report this afternoon, wher it reiterates its Hold rating on Verenium Corp. (NASDAQ: VRNM); it has a $2.90 price target on the name. The Jefferies analyst cited the company’s recent earnings report, which beat estimates; product revenues in the...

Jefferies & Co. is rating shares of Orexigen Therapeutics (NASDAQ: OREX) a Buy and has a $12 price target on the pharmaceutical company after it reported second quarter results last week. In the report Jefferies & Co. writes, "Orexigen reported an uneventful Q2 and did a great job on the...

Analysts at Jefferies & Co reiterate their "hold" rating on Oshkosh Corp (NYSE: OSK), while revising their estimates for the company. The target price for OSK has been reduced from $38 to $36. OSK reported better-than-expected Q3 earnings. Jefferies says, “While improved access profitability...

Jefferies & Company is out with a research report this morning, where it places Valeant Pharmaceuticals (NYSE: VRX) on its restricted list due to the company’s current role as an advisor to its merger with Biovail (NYSE: BVF). Prior to the merger, the company was Buy rated, with a $57.00 price...

Jefferies & Co. is out with a research report this morning, where it reiterates its Hold rating on Bruker Corp. (NASDAQ: BRKR); it has a $15.00 price target on the stock. The Jefferies analysts said that they are raising estimates on the name with 2010 EPS at $0.60 from $0.57, following BRKR's...

Jefferies & Co. is reiterating its Hold rating on shares of Computer Programs (NASDAQ: CPSI) after the healthcare information technology comapny beat quarterly earnings estimates. Jefferies has a price target of $42, below the current share price. In the note to investors Jefferies says, "...

Pre-open movers US stock futures jumped up today, driven by impressive earnings reported by HSBC Holdings (NYSE: HBC). While futures on the Dow Jones Industrial Average climbed 126 points to 10,543, those on the S&P 500 added 15.40 points to 1,114. Meanwhile, Nasdaq 100 futures gained 21.25...

Jefferies & Co is keeping its Hold rating and $50 price target Fortune Brands (NYSE: FO) after the diversified consumer products maker reported second quarter earnings. In a note to clients Jefferies writes, [We are] "Holding FY 2010E despite 2Q upside due to a reduced 2H outlook. While 2Q...

Jefferies & Co is lowering its earnings estimates on Colgate-Palmolive (NYSE: CL) after the consumer products maker reported weak sales numbers in the second quarter. Jefferies rates shares as a Hold and has price target of $85. In the report Jefferies writes, "While CL's 2Q earnings were...

Jefferies & Co is raising its price target on shares of Nu Skin Enterprises (NYSE: NUS) to $38 from $36 after the company beat earnings estimates last week. Jefferies rates Nu Skin as a Buy. In the report, Jefferies writes, "We are once again raising estimates, as NUS continues to enjoy the...

Analysts at Jefferies & Co upgrade Boyd Gaming Corporation (NYSE: BYD) from "underperform" to "hold." The target price for BYD has been raised from $7 to $9.50. BYD’s shares lost 0.94% to close at $8.46 on Friday. More Analyst Ratings here Learn how to find the best stocks to trade each day in...

Analysts at Jefferies & Co reiterate their "hold" rating on Symantec Corp (NASDAQ: SYMC), while reducing their estimates for the company. The target price for SYMC has been reduced from $17 to $15. According to Jefferies & Co, “Sales of Foundation Suite and Cluster Server dropped 5% q/q or...

Jefferies & Co is currently reviewing its price target on shares of Genzyme (NASDAQ: GENZ) due to speculation that Genzyme is a possible acquisition target. In the report, Jefferies writes, "Given the recent run-up in GENZ shares on take-out speculations (~24%), our PT is under review. On our...